Your browser doesn't support javascript.
loading
Generation and characterization of NGLY1 patient-derived midbrain organoids.
Abbott, Joshua; Tambe, Mitali; Pavlinov, Ivan; Farkhondeh, Atena; Nguyen, Ha Nam; Xu, Miao; Pradhan, Manisha; York, Tate; Might, Matthew; Baumgärtel, Karsten; Rodems, Steven; Zheng, Wei.
  • Abbott J; National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, United States.
  • Tambe M; National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, United States.
  • Pavlinov I; National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, United States.
  • Farkhondeh A; National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, United States.
  • Nguyen HN; Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
  • Xu M; 3Dnamics, Inc., Baltimore, MD, United States.
  • Pradhan M; National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, United States.
  • York T; National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, United States.
  • Might M; NeuroScience Associates Inc, Knoxville, TN, United States.
  • Baumgärtel K; University of Alabama at Birmingham, Birmingham, AL, United States.
  • Rodems S; Travere Therapeutics, San Diego, CA, United States.
  • Zheng W; Travere Therapeutics, San Diego, CA, United States.
Front Cell Dev Biol ; 11: 1039182, 2023.
Article en En | MEDLINE | ID: mdl-36875753
NGLY1 deficiency is an ultra-rare, autosomal recessive genetic disease caused by mutations in the NGLY1 gene encoding N-glycanase one that removes N-linked glycan. Patients with pathogenic mutations in NGLY1 have complex clinical symptoms including global developmental delay, motor disorder and liver dysfunction. To better understand the disease pathogenesis and the neurological symptoms of the NGLY1 deficiency we generated and characterized midbrain organoids using patient-derived iPSCs from two patients with distinct disease-causing mutations-one homozygous for p. Q208X, the other compound heterozygous for p. L318P and p. R390P and CRISPR generated NGLY1 knockout iPSCs. We demonstrate that NGLY1 deficient midbrain organoids show altered neuronal development compared to one wild type (WT) organoid. Both neuronal (TUJ1) and astrocytic glial fibrillary acid protein markers were reduced in NGLY1 patient-derived midbrain organoids along with neurotransmitter GABA. Interestingly, staining for dopaminergic neuronal marker, tyrosine hydroxylase, revealed a significant reduction in patient iPSC derived organoids. These results provide a relevant NGLY1 disease model to investigate disease mechanisms and evaluate therapeutics for treatments of NGLY1 deficiency.
Palabras clave